Jonathan Ledermann, MD

Jonathan Ledermann, MD, professor of oncology, UCL Cancer Institute, University College London, discusses the results of a subanalysis from the phase III ARIEL trial of rucaparib (Rubraca) maintenance treatment for patients with recurrent ovarian carcinoma.

In the phase III ARIEL trial, an intention-to-treat analysis showed that all subgroups of patients responded to rucaparib maintenance with an improvement in progression-free survival. The greatest benefit was seen in patient with

Study investigators conducted a second analysis, which looked at the effect of rucaparib in patients who had either a partial response (PR) or complete response (CR) to chemotherapy to see if rucaparib could further reduce the tumor burden. Results from this second analysis were presented at the 2019 ESMO Congress and showed that the benefit of rucaparib was seen in the patients who had a CR and in those who had a PR. In fact, the magnitude of the effect of rucaparib was similar in both groups.

Additionally, a proportion of patients who had measurable disease by the time they ended chemotherapy had a further response to rucaparib. In patients with

-mutated disease, the response rate was 37%. These results show that rucaparib is not only an effective maintenance therapy, but also a drug of therapeutic value in patients with ovarian cancer, says Ledermann.

Videos

Jonathan Ledermann, MD, professor of oncology, UCL Cancer Institute, University College London, discusses the results of a subanalysis from the phase III ARIEL trial of rucaparib maintenance treatment for patients with recurrent ovarian carcinoma.

Rucaparib May Improve PFS in Patients With Ovarian Cancer

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses phase III results of a study of rucaparib versus placebo following response to platinum-based chemotherapy for recurrent ovarian cancer.

Phase III Results for Rucaparib in Ovarian Cancer

Jonathan Ledermann, MD, professor of medical oncology in the University College London Cancer Institute and director of Cancer Research UK and UCL Cancer Trials Centre, discusses the toxicities associated with rucaparib (Rubraca) for the treatment of ovarian cancer.

Jonathan Ledermann, MD | Authors

Articles

Rucaparib May Improve PFS in Patients With Ovarian Cancer

Phase III Results for Rucaparib in Ovarian Cancer

Toxicities Associated With Rucaparib for the Treatment of Ovarian Cancer